Papathanasiou, Stamatis http://orcid.org/0000-0001-6969-044X
Markoulaki, Styliani
Blaine, Logan J. http://orcid.org/0000-0003-0937-9216
Leibowitz, Mitchell L. http://orcid.org/0000-0003-1874-5441
Zhang, Cheng-Zhong http://orcid.org/0000-0001-8825-7158
Jaenisch, Rudolf http://orcid.org/0000-0002-2540-7099
Pellman, David http://orcid.org/0000-0001-5306-8031
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (1U19AI131135-01)
Howard Hughes Medical Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA213404)
Article History
Received: 22 August 2021
Accepted: 13 September 2021
First Online: 6 October 2021
Competing interests
: C.-Z.Z. is a scientific adviser for Pillar BioSciences. R.J. is an advisor/co-founder of Fate Therapeutics, Fulcrum Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics. D.P. is a member of the Volastra Therapeutics scientific advisory board. All other authors declare no competing interests.